System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Alessandro Gozzetti is an expert in Hematology at Azienda Ospedaliera Universitaria Senese (Italy). As of October 2026, ScienceLeadR ranks Alessandro Gozzetti in the top 1% of experts worldwide for Lymphoproliferative Disorders. Alessandro Gozzetti has authored 309 publications, the most recent in 2026, and is an investigator in 9 clinical trials, 4 of them ongoing. SLR score: 952 (community average: 125). How the SLR is computed.

LeadR Profile

Alessandro Gozzetti Azienda Ospedaliera Universitaria Senese Italy
952 ScienceLeadR Reputation 952

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Immunology - Cardiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2000 - 2026
Source: PubMed

University of Siena

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 309

Citations

Citations: 7 528 1st author: 78 Last author: 9 Unique author: 6

Main journals

Blood 54
Cancer Genet Cytogenet 15
Haematologica 14
Br J Haematol 13
Leuk Lymphoma 12

Best Journals

Lancet Oncol 4
Eur Heart J 1
J Clin Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Immunomodulatory Receptor ILT3/LILRB4 Protects Human Leukemic B Cells From Ferroptosis In Vitro.
PMID 42847431 — cells, cell proliferation, lymph nodes, neoplasms, leukemia, lymphocytic, chronic, b-cell, ferroptosis, leukemia, lymph, b-lymphocytes		Eur J Immunol20260
Taginostat, a new quinolone-based HDAC6 inhibitor, promotes apoptosis of chronic lymphocytic leukemia cells in vitro and in vivo by activating STAT4.
PMID 42400850 — quinolones, cells, stat4 transcription factor, cell survival, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, therapeutics, apoptosis		Apoptosis20260
Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.
PMID 41980020 — cells, leukemia, hairy cell, hematology, leukemia, diagnosis, therapeutics		Blood20260
MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MM.
PMID 41888038 — progression-free survival, multiple myeloma, therapeutics		Br J Haematol20260
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.
PMID 41881954 — multiple myeloma, therapeutics		Blood Cancer J20260

Clinical Studies 9

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 4
Phase 2 3
N/A 2

By status:

Recruiting 3
Unknown 3
Completed 2
Active not recruiting 1

By type:

Interventional 7
Observational 2

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 0
multicentricup10 5

Main Topics

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
MagnetisMM 6 A Phase 3 Study of Elranatamab (PF 06863135) Daratumumab Lenalidomide Versus Daratumumab Bortezomib Lenalidomide Dexamethasone in Transplant Ineligible Participants With Newly Diagnosed Multiple Myeloma
2024-514139-50-00 — safety, dexamethasone, bortezomib, multiple myeloma, lenalidomide, transplants		Phase 3Recruiting2022
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide Bortezomib Dexamethasone (PVd) or Carfilzomib Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy Including an Anti CD38 Monoclonal Antibody and Lenalidomide
2023-503444-13-00 — dexamethasone, bortezomib, multiple myeloma, antibodies, monoclonal, lenalidomide, therapeutics		Phase 3Active not recruiting2023
VEMURAFENIB PLUS RITUXIMAB AS A CHEMOTHERAPY FREE ALTERNATIVE TO CLADRIBINE FOLLOWED BY MRD GUIDED RITUXIMAB IN FRONT LINE HAIRY CELL LEUKEMIA (HCL) A PHASE 2 RANDOMIZED MULTICENTER TRIAL
2024-520119-41-00 — cells, leukemia, hairy cell, leukemia, drug therapy, rituximab, cladribine, diagnosis, therapeutics, vemurafenib, chemotherapy		Phase 2Recruiting2023
Study on the Diagnosis and Management of CLL in Italy by GIMEMA
NCT04867915 — cells, lymphoma, lymphocytosis, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, diagnosis, b-lymphocytes		N/ARecruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS